In Segment C, participants will obtain ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Participants will receive treatment right until condition progression or perhaps the individuals are not able to tolerate the study drugs. - "Our study disclosed the critical role with the KLF16/MYC regulatory https://abbv-744-preclinical-stud57913.blogdosaga.com/32024198/a-review-of-abbv-744-in-combination-with-immunotherapy